Why the study?
Second generation DES were developed to reduce rates of late and very late complications of first generation DES and improve long-term efficacy and safety in patients undergoing PCI.
Second generation drug-eluting stents are considered the gold standard treatment for patients undergoing PCI for stable and acute coronary syndromes due to their improved safety and efficacy profiles.
Answers are grounded in this paper and cite their sources.
Supports second-generation DES preference in PCI; leaves open need for prospective comparisons with newer platforms.
Introduction: Percutaneous coronary intervention (PCI) represents the most frequent procedure performed in medicine. Second generation drug eluting stents (DES) have been developed to reduce the rates of late and very late complications of first generation DES.Areas covered: To improve long-term efficacy and safety of patients undergoing PCI, second generation DES have been developed with novel stent platforms, biocompatible durable and biodegradable polymers and newer antiproliferative agents. In this review we provide an overview of second generation DES and their clinical trials, discussing safety and effectiveness of these devices, and outlining clinical indication for use.Expert commentary: Numerous clinical trials have demonstrated the safety and efficacy of second generation DES over the last decade. These devices represent the gold standard treatment in stable and acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Spione et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: